|Bid||17.40 x 100000|
|Ask||17.50 x 100000|
|Day's Range||17.40 - 17.40|
|52 Week Range||7.13 - 23.81|
|Beta (3Y Monthly)||-0.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc ...
Iovance Biotherapeutics is worth speculating on, as the company's cancer treatments are promising, Jim Cramer said during his Mad Money program Friday night. IOVA intends to commercialize "autologous cell therapy products for solid tumors and blood cancers." Their approach uses a patient's own immune cells to attack cancer cells -- cutting edge stuff, if you ask me. In the daily bar chart of IOVA, below, we can see that prices made a seven-plus month base around $10 before a gap to the upside got the rally going.
Iovance Biotherapeutics hit a "clear inflection point" in the second quarter, analysts said Friday — but that didn't stop the biotech stock from plunging on wider-than-expected losses.
Since the beginning of the year, the company has announced a new collaborations with Glycostem Therapeutics, the promotion of Dr. Gerrit Dispersyn to CEO and the appointment of Dr. John Barrett as CDO. Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes.
Iovance shares have climbed more than 50 percent since its data was first released in mid-May, including a 10 percent surge on Monday (the company presented at the Chicago conference on Friday). Amgen shares climbed more than 4 percent this week, while Mirati Therapeteutics Inc. – a smaller rival that’s working on a similar lung cancer drug to Amgen’s surged more than 45 percent in that same time. It’s easy to over-hype initial results, and there have been many instances where thrilling early data and a ballooning stock price deteriorated over time. In the case of Iovance and Amgen, though, the excitement is warranted, and the impact should extend beyond a few amped-up investors.
Iovance Biotherapeutics stock popped in high volume Thursday after the Food and Drug Administration granted it accelerated development of its cervical cancer treatment known as LN-145.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Axsome Therapeutics Inc (NASDAQ: AXSM ) Milestone Pharmaceuticals ...
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Label expansionOn March 28, Amarin (AMRN) issued a press release announcing the submission of an sNDA (supplemental new drug application) to the FDA seeking
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Vascepa demand in the first quarterIn the first quarter, Amarin (AMRN) reported net product sales of $72.7 million, a YoY rise of 66%. According to
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?(Continued from Prior Part)Revenue guidanceIn its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which
Amarin or Iovance Biotherapeutics: Which Is a Better Pick in May?Stock price movementsOn May 17, Amarin (AMRN) closed at $17.79, 2.30% higher than the previous close, 657.02% higher than the 52-week low of $2.35, and 23.76% lower than the 52-week
Shares of small-cap biotech Iovance Biotherapeutics Inc (NASDAQ: IOVA ) were making a strong upward move Thursday on more than 10 times their average volume. Iovance announced multiple updates in conjunction ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...
On a per-share basis, the San Carlos, California-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment ...